Sandoz’ global partnership with Gan & Lee Pharmaceuticals has passed another milestone, with the Chinese firm announcing the completion of two randomized, multi-center, Phase III clinical studies comparing its proposed GL-GLA biosimilar insulin glargine biosimilar to the reference biologic, Sanofi’s Lantus.
“The primary purpose of these 26-week studies” – one in subjects with type 1 diabetes and the other in subjects...